Altered PD-L1 expression in non-small cell lung cancer patient after induction chemotherapy: A case report

Targeting the immune checkpoint of programmed death ligand 1 (PDL1) and programmed cell death protein 1 (PD-1) with immunotherapy has improved the treatment of many tumors including non-small cell lung cancer (NSCLC). Checking PD-L1 status must be done during the course of therapy.